Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma-Reference-Cited by-同舟云学术

Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma

Published:2020-11-19 Issue:11 Volume:2020 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Tomita Yoko¹,Moldovan Max²,Chang Lee Rachael³,Hsieh Amy HC¹,Townsend Amanda¹,Price Timothy¹

Affiliation:

1. Medical Oncology; The Queen Elizabeth Hospital and University of Adelaide; Woodville, Adelaide Australia

2. South Australian Health and Medical Research Institute; Adelaide Australia

3. Department of Medical Oncology; Adelaide Cancer Centre; Windsor Gardens Australia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference176 articles.

1. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial;Bang;Lancet Oncology,2017

2. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial;Hironaka;Journal of Clinical Oncology,2013

3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet,2017

4. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer;Kim;Anticancer Research,2015

5. A multicenter randomized phase II Study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus Either S-1 or capecitabine;Lee;Cancer Research and Treatment,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice;International Journal of Molecular Sciences;2024-03-30

2. Optimizing the Continuum of Care in Gastric Cancer;OncoTargets and Therapy;2023-11

3. Deficient Mismatch Repair Proteins in Gastric Mixed Neuroendocrine Non-Neuroendocrine Neoplasm: A Rare Case Report;Case Reports in Oncology;2023-10-17

4. Comparison of the Efficacy of FOLFIRI and Paclitaxel Chemotherapy Regimens in the Second Line Treatment of Metastatic Gastric Cancer;Van Sağlık Bilimleri Dergisi;2023-08-30

5. Prognostic factors for overall survival in stage IV gastric cancer;Số 86 (English);2023-03-12